Literature DB >> 30111259

Effectiveness of annual single doses of diethylcarbamazine citrate among bancroftian filariasis infected individuals in an endemic area under mass drug administration in Brazil.

Jennifer S F da Silva1, Cynthia Braga1, Felipe M Duarte2, Paula Oliveira1, Carlos Feitosa Luna1, Márcia Marcondes3, Josué Araújo1, Maria Rosangela Grilis1, Paula Fernanda A de Souza Melo1, Eduardo Brandão1, Abraham Rocha1,4.   

Abstract

The Global Program to Eliminate Lymphatic Filariasis has achieved extraordinary success in reducing transmission and preventing morbidity through mass drug administration (MDA) to the population at-risk. Brazil is the only currently using diethylcarbamazine citrate (DEC) alone for MDA, so an assessment of its effectiveness is needed. We report the trends of filarial markers in a cohort of 175 individuals infected with Wuchereria bancrofti in areas that underwent MDA in the city of Olinda, Northeastern Brazil. The prospective study was conducted between 2007 and 2012 (corresponding to five annual MDA rounds). The quantification of microfilaraemia (QMFF) was assessed by filtration. Circulating filarial antigen (CFA) was detected through immunochromatographic point-of-care test (POCT-ICT) and Og4C3-ELISA whereas antifilarial antibody titres (IgG4) were assessed through Bm14 assay. The CFA and IgG4 titres were measured by Optical Density (OD). The main characteristics at baseline, MDA coverage and the trend of filarial infection markers during follow up were described. The trend of filarial markers in relation to time (years of MDA), sex and age were analysed through Generalized Estimating Equations (GEE) models. The models demonstrated a significant decrease in all markers during MDA. The probability of remaining positive by QMFF and POCT-ICT diminished 70% and 46%, respectively, after each MDA round. There was a significant annual drop in CFA (-0.290 OD) and IgG4 antibodies titres (-0.303 OD). This study provides evidence that MDA with DEC alone can be effective in the elimination of LF in Brazil.

Entities:  

Keywords:  Lymphatic filariasis; Wuchereria bancrofti; diethylcarbamazine citrate; mass drug administration; prevention and control

Mesh:

Substances:

Year:  2018        PMID: 30111259      PMCID: PMC6225505          DOI: 10.1080/20477724.2018.1498821

Source DB:  PubMed          Journal:  Pathog Glob Health        ISSN: 2047-7724            Impact factor:   2.894


  27 in total

1.  Statistical analysis of correlated data using generalized estimating equations: an orientation.

Authors:  James A Hanley; Abdissa Negassa; Michael D deB Edwardes; Janet E Forrester
Journal:  Am J Epidemiol       Date:  2003-02-15       Impact factor: 4.897

2.  Field evaluation of the whole blood immunochromatographic test for rapid bancroftian filariasis diagnosis in the northeast of Brazil.

Authors:  Cynthia Braga; Maria Inês Dourado; Ricardo Arraes de A Ximenes; Luiz Alves; Fabio Brayner; Abraham Rocha; Neal Alexander
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2003-07-08       Impact factor: 1.846

3.  Efficacy of single-dose diethylcarbamazine compared with diethylcarbamazine combined with albendazole against Wuchereria bancrofti infection in Papua New Guinea.

Authors:  Moses J Bockarie; Livingstone Tavul; Irvin Ibam; Will Kastens; Fred Hazlett; Daniel J Tisch; Michael P Alpers; James W Kazura
Journal:  Am J Trop Med Hyg       Date:  2007-01       Impact factor: 2.345

4.  Mass drug administration trial to eliminate lymphatic filariasis in Papua New Guinea: changes in microfilaremia, filarial antigen, and Bm14 antibody after cessation.

Authors:  Daniel J Tisch; Moses J Bockarie; Zachary Dimber; Benson Kiniboro; Nandao Tarongka; Fred E Hazlett; Will Kastens; Michael P Alpers; James W Kazura
Journal:  Am J Trop Med Hyg       Date:  2008-02       Impact factor: 2.345

5.  Comparison of tests for the detection of circulating filarial antigen (Og4C3-ELISA and AD12-ICT) and ultrasound in diagnosis of lymphatic filariasis in individuals with microfilariae.

Authors:  Abraham Rocha; Cynthia Braga; Marcela Belém; Arturo Carrera; Ana Aguiar-Santos; Paula Oliveira; Maria José Texeira; André Furtado
Journal:  Mem Inst Oswaldo Cruz       Date:  2009-07       Impact factor: 2.743

6.  Eliminating lymphatic filariasis--the surveillance challenge.

Authors:  Clare Huppatz; David Durrheim; Patrick Lammie; Paul Kelly; Wayne Melrose
Journal:  Trop Med Int Health       Date:  2008-03       Impact factor: 2.622

7.  Global programme to eliminate lymphatic filariasis: progress report, 2013.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2014-09-19

8.  Adverse reactions following mass drug administration with diethylcarbamazine in lymphatic filariasis endemic areas in the Northeast of Brazil.

Authors:  Ana Wládia Lima; Zulma Medeiros; Zailde Carvalho Dos Santos; Gertrudes Monteiro da Costa; Cynthia Braga
Journal:  Rev Soc Bras Med Trop       Date:  2012-12       Impact factor: 1.581

Review 9.  Albendazole for lymphatic filariasis.

Authors:  Julia Critchley; D Addiss; C Gamble; P Garner; H Gelband; H Ejere
Journal:  Cochrane Database Syst Rev       Date:  2005-10-19

10.  Children and adolescents infected with Wuchereria bancrofti in Greater Recife, Brazil: a randomized, year-long clinical trial of single treatments with diethylcarbamazine or diethylcarbamazine-albendazole.

Authors:  J A Rizzo; C Belo; R Lins; G Dreyer
Journal:  Ann Trop Med Parasitol       Date:  2007-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.